IV selexipag can be used as a bridging therapy

PHA Canada
Jun 9, 2025
1 min read

Pulmonary arterial hypertension patients who take selexipag normally take it orally (as a pill). Sometimes, though, this is temporarily impossible. People might be unable to swallow or have other medical conditions that interfere with their ability to take pills. A small study looked at whether temporarily giving selexipag as an intravenous infusion was safe and effective. They found that it was.

Read the Therapeutics and Clinical Risk Management paper

Recent Posts

Environmental triggers may contribute to heritable PAH

This study tried to identify new environmental triggers or genetic causes in heritable pulmonary arterial hypertension. They found several potential genes for further exploration, but they also found

Time to diagnosis matters for patients with PAH

This study identified factors associated with a delayed diagnosis of PAH and found that earlier diagnosis (<6 months) and treatment initiation were associated with significantly improved survival. Mor

Review finds selexipag is well tolerated in children

A review of 12 studies evaluating selexipag in pediatric patients with pulmonary arterial hypertension found that it improved functional capacity and mPAP, especially when added to existing therapies.

Comments